Enhancing the Efficacy of Immunotherapeutic Drugs for Prostate Cancer – Dr Douglas McNeel, MD PhD, University of Wisconsin

Apr 25, 2019 | biology, health and medicine

Original Article Reference


About this episode

Prostate cancer is a leading cause of male cancer deaths worldwide, with one man in every seven likely to contract the disease during his lifetime. As late-stage prostate cancer remains a fatal disease resistant to conventional treatment, the need for effective new therapies is dire. Dr Douglas McNeel, a Professor of Medicine in the Haemato-Oncology Division of the University of Wisconsin’s Carbone Cancer Centre, has been working to meet this need.


This work is licensed under a Creative Commons Attribution 4.0 International LicenseCreative Commons License

What does this mean?

Share: You can copy and redistribute the material in any medium

or format

Adapt: You can change, and build upon the material for any

purpose, even commercially.

Credit: You must give appropriate credit, provide a link to the

license, and indicate if changes were made.

Increase the impact of your research

• Good science communication helps people make informed decisions and motivates them to take appropriate and affirmative action.

• Good science communication encourages everyday people to be scientifically literate so that they can analyse the integrity and legitimacy of information.

• Good science communication encourages people into STEM-related fields of study and employment.

• Good public science communication fosters a community around research that includes both members of the public, policymakers and scientists.

• In a recent survey, 75% of people suggested they would prefer to listen to an interesting story than read it.

Step 1

Upload your science paper

Step 2

SciPod script written

Step 3

Voice audio recorded

Step 4

SciPod published